<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The effect of <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> on foetal <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> (HbF) levels was evaluated in 36 patients of myeloproliferative and <z:mpath ids='MPATH_341'>myelodysplastic disorders</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>In 17 (47.2%) patients, HbF levels increased from 1.40 +/- 1.17 to 3.03 +/- 1.97 per cent after 4 wk therapy with <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>In the responders this increase was highly significant (P less than 0.001) </plain></SENT>
<SENT sid="3" pm="."><plain>The rise in the HbF levels after <z:chebi fb="0" ids="44423">hydroxyurea</z:chebi> therapy was significant in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> but not in the other groups </plain></SENT>
</text></document>